This technology utilizes red ginseng-derived ginsenoside Rg3 as an active ingredient to restore the function of umbilical cord blood stem cells from mothers with preeclampsia and promote their differentiation into vascular endothelial cells. It consists of pharmaceutical, food, and cosmetic compositions for the prevention and treatment of preeclampsia caused by restricted placental blood flow.
Preeclampsia is increasing significantly due to the rise in late marriages and advanced maternal age, and it is the leading cause of maternal mortality, leading to hypertension, edema, proteinuria, fetal growth restriction, and preterm birth. While restricted blood flow during placental formation is a primary cause, there has been a lack of fundamental preventive and therapeutic means to address it.
This technology enables ginsenoside Rg3 to restore the proliferation, migration, adhesion, differentiation, wound healing, and angiogenic capabilities of vascular stem cells derived from the umbilical cord blood of mothers with preeclampsia. This promotes placental angiogenesis and alleviates blood flow restriction. It can be applied to obstetric therapeutics and functional materials for pregnant women, offering a new approach to high-risk pregnancy management using natural red ginseng components.
N/A
